about their prevalence and clinical characteristics. To clarify the prevalence and clinical characteristics of airway diseases associated with UC, we retrospectively assessed patients with UC and airway diseases at our hospital.
three with inhalation and oral corticosteroid, and two were refractory to oral corticosteroid and thus were treated with corticosteroid, oral corticosteroid, and tacrolimus.
Conclusion:
The frequency of clinically significant airway diseases in UC was approximately 1%.
Almost all patients underwent colectomy, and airway diseases developed within 1 year after colectomy. In refractory cases, tacrolimus seems to be effective. Background and Aims: It's common that children with allergy received local adverse reactions after SCIT and their symptoms were light and easy to be relieved. To observe children with allergy who received adverse reactions after house dust mites specific subcutaneous immunotherapy (SCIT), and excavate the risk factors of adverse reactions, in order to provide more information for clinical practice of SCIT.
AP063 ANALYSIS OF ADVERSE REACTIONS AND RISK FACTORS

Methods:
The clinical data was collected and retrospectively analyzed in child patients with allergy who received SCIT from December 2007 to July 2013 in Department of Pediatrics, First Affiliated Hospital of Guangzhou Medical University. We calculated the incidence of local and systemic adverse reactions, and made the analysis by using GAMMs to find the risk factors that may produce adverse reactions.
Results: Among 163 patients who received SCIT have 7870 injections. An average of 48.28 injections were received, with a minimum of 14 injections and a maximum of 67 injections. The incidence of local and systemic adverse reactions were 21.21% and 2.21% respectively. The clinical symptoms and signs of local adverse reactions mainly were localwheal, vaccinal areola, pruritus and induration which could alleviate by oneself; the clinical symptoms and signs of systemic adverse reactions was acute attack of asthma which could alleviate after spray treatment timely. The results of analysis showed that gender, month, weeklyinjection and dose were statistically significant (P > 0.05).These may be the risk factors of adverse reactions.
Conclusion: In our research, the incidence of systemic adverse reactions was low and the degree of systemic adverse reactions was mild and moderate. It may be severe so that we need to control closely. The risk factors of adverse reactions included female, September, 50 weeklyinjection and the dose is over 75,000SQ. Methods: In this cross-sectional survey across six countries, 1204 physicians (general physicians and paediatricians) were interviewed using a structured questionnaire that included 3 hypothetical case studies to understand physicians' assessment practices, diagnosis and treatment of coexistent disease using practical examples. Results for the case studies are presented.
Results: In a case study of a 12-year-old boy with asthma, presenting with nasal and ocular symptoms of AR (Figure 1) , the most common follow-up was assessment of both nasal and asthma symptoms. 75% of physicians diagnosed coexistent asthma and AR, and the most commonly prescribed treatment was inhaled corticosteroids (Figure 1 ). There was variation across countries in the diagnosis of this case with interviewed physicians in China, Malaysia and Thailand being more likely to diagnose coexistent disease (93%%, 92% and 94% respectively), while physicians in the Philippines being less likely (35%), showing a higher tendency to diagnose one disease. Similar results were observed for the other case studies, which included a 32-year-old female with AR presenting with symptoms of wheeze and breathlessness on exertion, and a 25-year-old male with a history of atopy, presenting with breathlessness, wheezing, sneezing, nasal congestion, and watering of eyes.
Conclusion:
These data suggest an under-diagnosis of coexistent asthma and AR in the Asia-Pacific region, but this varies across countries, with physicians interviewed in China, Malaysia and Thailand most likely to diagnose co-existent disease, and the Philippines least likely. Overall, inhaled corticosteroids are commonly utilized in patients with co-existent disease, while intranasal corticosteroids appear to be underutilized in this population.
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